These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30410365)

  • 1. Novel EXO-T vaccine using polyclonal CD4
    Li R; Chibbar R; Xiang J
    Onco Targets Ther; 2018; 11():7089-7093. PubMed ID: 30410365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.
    Datta J; Berk E; Xu S; Fitzpatrick E; Rosemblit C; Lowenfeld L; Goodman N; Lewis DA; Zhang PJ; Fisher C; Roses RE; DeMichele A; Czerniecki BJ
    Breast Cancer Res; 2015 May; 17(1):71. PubMed ID: 25997452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
    Woll MM; Fisher CM; Ryan GB; Gurney JM; Storrer CE; Ioannides CG; Shriver CD; Moul JW; McLeod DG; Ponniah S; Peoples GE
    J Clin Immunol; 2004 Jul; 24(4):449-61. PubMed ID: 15163902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient Acquisition of Fully Human Antibody Genes against Self-Proteins by Sorting Single B Cells Stimulated with Vaccines Based on Nitrated T Helper Cell Epitopes.
    Jiang L; Jiang T; Luo J; Kang Y; Tong Y; Song X; Gao X; Yao W; Tian H
    J Immunol Res; 2019; 2019():7914326. PubMed ID: 32083142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing anti-HER2 vaccines: Breast cancer experience.
    Al-Awadhi A; Lee Murray J; Ibrahim NK
    Int J Cancer; 2018 Nov; 143(9):2126-2132. PubMed ID: 29693245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyclonal antibodies against gp185HER2 peptides: their putative role in the identification of a particular HER2 status in patients with breast cancer.
    Di Modugno F; Buglioni S; Mottolese M; Bello DD; Cascioli S; Chersi A; Santoni A; Nisticò P
    J Immunother; 2001; 24(3):221-31. PubMed ID: 11394499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a cancer vaccine: peptides, proteins, and DNA.
    Shiku H; Wang L; Ikuta Y; Okugawa T; Schmitt M; Gu X; Akiyoshi K; Sunamoto J; Nakamura H
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S77-82. PubMed ID: 10950153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
    Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
    Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
    Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
    Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer.
    Di Modugno F; Buglioni S; Mottolese M; Del Bello D; Cascioli S; Chersi A; Santoni A; Nisticò P
    J Immunother (1991); 2001 May; 24(3):221-231. PubMed ID: 11395637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation.
    Barok M; Puhka M; Vereb G; Szollosi J; Isola J; Joensuu H
    BMC Cancer; 2018 May; 18(1):504. PubMed ID: 29720111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.
    D'Amico L; Menzel U; Prummer M; Müller P; Buchi M; Kashyap A; Haessler U; Yermanos A; Gébleux R; Briendl M; Hell T; Wolter FI; Beerli RR; Truxova I; Radek Š; Vlajnic T; Grawunder U; Reddy S; Zippelius A
    J Immunother Cancer; 2019 Jan; 7(1):16. PubMed ID: 30665463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.